| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Recursion Pharmaceuticals, Inc. (RXRX) has 7 insiders with recent SEC Form 4 filings, including 2 buys and 2 sells. RXRX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 6.65M | $21.48M | - | |
| Dir | 4.52M | $14.61M | - | |
| CEO | 2.26M | $7.31M | - | |
| Dir | 1.24M | $4.01M | - | |
| Other | 1.11M | $3.58M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2021 | Borgeson Blake69 | Director | Sell | 9,625 | $18.91 | $182,005.12 | - | -39.6% | -48.9% | |
| Apr 16, 2021 | Mubadala Investment Co Pjsc62 | 10% Owner | Buy | 2,777,777 | $18.00 | $49,999,986.00 | New | +3.8% | -79.1% | |
| Apr 16, 2021 | Lux Ventures Iv, L.P. | 10% Owner | Buy | 100,000 | $18.00 | $1,800,000.00 | New | +3.8% | -79.1% |